Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Prostatic Neoplasms

Genetic Predisposition to Disease

Disease Susceptibility

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Familial Prostate Cancer

saliva samples will be collected from men (probands) who join the study.

DNA analysis

we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis

polymorphism analysis

10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses

laboratory biomarker analysis

PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis

medical chart review

probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study

questionnaire administration

pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors

evaluation of cancer risk factors

prostate biopsy pathology reports will be reviewed for high risk factors

study of high risk factors

Jackilen Shannon, PhD

RATIONALE: Gathering information about genetic and environmental factors may help doctors learn more about a person's risk for developing prostate cancer.

PURPOSE: This research project is studying genes, environment, and prostate cancer risk in patients with or without prostate cancer.

OBJECTIVES:

* To determine the association between variation in genes involved in ROS detoxification, oxidative stress response, and prostate cancer risk.
* To determine the association between fatty acid levels and prostate cancer risk.

OUTLINE: Probands undergo blood and saliva sample collection for fatty acid, DNA, and polymorphism analyses. Archived blood and tissue samples from probands who previously participated in Dr. Shannon's Diet and Prostate Cancer Risk study are also analyzed. Medical records of probands are reviewed for demographics, history and course of disease, and clinical laboratory test results.

All probands completed the "Genetic Risk Easy Assessment Tool Family History of Cancer" and "Diet History and Environmental Risk Factor" questionnaires at baseline. If a proband previously participated on our Diet and Prostate Cancer Risk study, he was asked to complete the "Changes in Diet, Prescriptions, Supplementals and Herbal Remedies" questionnaire in addition to the "Genetic Risk Easy Assessment Tool Family History of Cancer" questionnaire at baseline for this study.

PROJECTED ACCRUAL: A total of 750 participants will be accrued for this study.

10ml blood specimen drawn from probands consented in person at the Portland VA; saliva samples from all consented probands (N = 748).

Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer

Genetic Susceptibility, Environment & Prostate Cancer Risk

Using saliva samples, we conducted analysis on probands' oxidative stress pathway genes and whether these were associated with prostate cancer risk.

Using blood samples, we conducted analysis on probands' fatty acid level and whether these were associated with prostate cancer risk.

Portland VA Medical Center

Staff Scientist

Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.

Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.

Family History: Number Format Subjects receive family history risk in a number format.

Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.

Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.

Genetic Risk Score: Number Format

Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Genetic Risk Score: Number + Pictograph

Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Family History: Number Format

Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Family History: Number + Pictograph

Jianfeng Xu, Dr.P.H.

This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.

ABSTRACT: This clinical trial registration is focused on Aim 4 within the overall project described in the following.

Prostate cancer (PCa) is the most common cancer among men in the U.S. One important strategy to address this public health concern is to prevent the disease. Two large randomized clinical trials, The Prostate Cancer Prevention Trial (PCPT) and The Reduction by Dutasteride of Prostate Cancer Events (REDUCE), have demonstrated a 23-25% reduction in PCa risk with the use of 5 alpha reductase inhibitors (5ARIs: finasteride and dutasteride). However, 5ARIs have not been widely adopted due, in part, to poor cost-effectiveness. We hypothesize that targeted chemoprevention, based on 1) overall genetic risk \[family history (FH) and PCa risk-associated genetic variants\], and 2) polymorphisms that interact with 5ARIs, may be more efficacious and cost-effective, and thus more likely to be employed by physicians and their patients. The effectiveness of this genomic-targeted approach needs to be systematically evaluated and compared to non-genomic approaches using evidence-based methods such as those recommended by the EGAPP (Evaluation of Genomic Applications in Practice and Prevention) working group. We have assembled a multidisciplinary research team to address an overarching question of whether a genomic-targeted approach improves outcomes related to chemoprevention of PCa using 5ARIs compared to a non-targeted approach. We will evaluate and compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches in two existing large randomized clinical trials (Reduction by Dutasteride of Prostate Cancer Events (REDUCE) and Prostate Cancer Prevention Trial (PCPT)), two new study populations of men at risk for PCa, and in a survey of physicians. The unique study design of REDUCE and PCPT, with end-of-study prostate biopsies, allows us to address two critical questions in this study: Prostate Specific Antigen (PSA) detection-bias of PCa risk-associated Single Nucleotide Polymorphisms (SNPs) and efficacy of genomic-targeted chemoprevention of PCa using 5ARIs. We have the following specific aims: 1) assess the clinical validity of PCa risk prediction models using a panel of non PSA detection biased PCa risk-associated SNPs. 2) identify and assess the clinical validity of novel polymorphisms that interact with 5ARIs in reducing PCa diagnosis using both genome-wide and candidate gene approaches, 3) assess the clinical utility of a genomic-targeted approach by comparing its reduction in rates of PCa with non-targeted chemoprevention, 4) compare perception and decision making of physicians and patients for genomic and non-genomic-targeted chemoprevention of PCa, and 5) Compare the cost-effectiveness of genomic and non-genomic-targeted chemoprevention of PCa. Results from this study will provide comprehensive data for evidence-based evaluation by the Center for Disease Control's Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group, provide a proof of principle study of Comparative Effectiveness Research (CER), and will help build a road map for future Genomic and Personalized Medicine (GPM) in the 21st century.

Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a

There is no intent to share individual participant data (IPD). The terms included in the study consent form do not allow sharing of IPD.

Discussion with Physician regarding PSA screening, measured by survey 3 months after provision of risk information

PSA screening, measured by survey 3 months after provision of risk information.

PSA screening, measured by medical records 3 years after provision of risk information.

Immediate reaction to risk information. Measured by state anxiety scale that assess current feelings "at this moment": 1) not at all, 2) somewhat, 3) moderately so, and 4) very much so. A shortened version of questions 1,3,5,9,11,12,13,15,17, and 19 from STAI form XI were used. Each item, within then STAI is scored on a scale of 1-4 and with 10 items, the possible range of total scores was 10 (lowest anxiety) to 40 (highest anxiety). Lowest scores represent better outcomes.

Mean between Immediate recall of risk information and told risk information. Immediate recall is measured by survey question: "Based on the information given to you, what were you told is your chance of developing prostate cancer in your lifetime from 0% to 100% ______ %"

Mean between recall of risk information at 3 months measured by survey, and told risk information. Recall at 3 months is measured by survey question: "Based on the information given to you, what were you told is your chance of developing prostate cancer in your lifetime from 0% to 100% ______ %"

Van Andel Research Institute

Spectrum Health Medical Group

National Cancer Institute (NCI)

Wake Forest University Health Sciences

NorthShore University HealthSystem

Professor of Human Genomics and Personalized Medicine, Epidemiology, Cancer Biology, and Urology

Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.

Genetic Risk Score: Number Format: Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.

Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.

Genetic Risk Score: Number + Pictograph: Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Family History: Number Format Subjects receive family history risk in a number format.

Family History: Number Format: Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.

Family History: Number + Pictograph: Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Total

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

Dr. Aubrey R. Turner

Number of Participants Who Had Prostate Specific Antigen (PSA) Discussion With Physician at 3 Months, Measured by Survey

Number of Participants Who Had PSA Testing at 3 Months, Measured by Survey

Number of Participants Who Had PSA Testing at 3 Years, Measured by Medical Records

Computerized randomization of 700 study identifiers into 175 blocks of four each was completed prior to enrollment. Genetic Risk Score=GRS and Family History=FH. Randomization groups were (Group 1) GRS+FH as a number; (Group 2) GRS+FH as a number and pictograph; (Group 3) FH as a number; and (Group 4) FH as a number and pictograph.

Anxiety, Measured by State-trait Anxiety Inventory (STAI)

The statistical analysis shows the relation between risk given and risk recall at the immediate post results assessment for the total number of participants.

Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format. Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number. Data presented as linear relationship between told risk and immediate recall.

Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format. Genetic Risk Score: Number + Pictograph: Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group. Data presented as linear relationship between told risk and immediated recall.

Family History: Number Format Subjects receive family history risk in a number format. Family History: Number Format: Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group. Data presented as linear relationship between told risk and immediated recall.

Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format. Family History: Number + Pictograph: Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group. Data presented as linear relationship between told risk and immediated recall.

Accuracy of Immediate Recall of Risk Information Measured by Survey

Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format. Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number. Data presented as linear relationship between told risk and immediated recall.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer	NCT01013129	Hereditary Pros... Prostate Cancer	DNA analysis polymorphism an... laboratory biom... medical chart r... questionnaire a... evaluation of c... study of high r...	21 Years - 120 Years	Portland VA Medical Center
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a	NCT02381015	Prostate Cancer Prostate Cancer... Hereditary Pros...	Genetic Risk Sc... Genetic Risk Sc... Family History:... Family History:...	40 Years - 49 Years	NorthShore University HealthSystem
Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer	NCT01013129	Hereditary Pros... Prostate Cancer	DNA analysis polymorphism an... laboratory biom... medical chart r... questionnaire a... evaluation of c... study of high r...	21 Years - 120 Years	Portland VA Medical Center

Spots Global Cancer Trial Database for hereditary prostate cancer